Home › Companies › Jazz Pharmaceuticals plc › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Jazz Pharmaceuticals plc’s Form 8-K, filed July 25, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of July 24, 2025: 7 items on Jazz Pharmaceuticals plc’s Form 8-K, filed July 25, 2025: 4 elected · 3 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Jazz Pharmaceuticals plc in the interactive database Compare manager voting policies
These tallies are Jazz Pharmaceuticals plc’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed July 25, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jennifer E. Cook | 49,838,761 | 1,472,373 | 31,182 | -- | 4,465,696 | 97% | Elected | — |
| Elect Director: Patrick G. Enright | 49,122,808 | 2,186,963 | 32,545 | -- | 4,465,696 | 96% | Elected | — |
| Elect Director: Seamus Mulligan | 49,488,355 | 1,821,942 | 32,019 | -- | 4,465,696 | 96% | Elected | — |
| Elect Director: Norbert G. Riedel, Ph.D. | 46,521,583 | 4,787,903 | 32,830 | -- | 4,465,696 | 91% | Elected | — |
| 2. To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as our independent auditors for the fiscal year ending December 31, 2025 and to authorize, in a binding vote, our board of directors, acting through the audit committee, to determin | 54,773,976 | 996,901 | 37,135 | -- | -- | 98% | Approved | — |
| 3. To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement | 48,261,149 | 2,887,574 | 193,593 | -- | 4,465,696 | 94% | Approved | — |
| 4. To grant our board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply | 53,607,244 | 2,159,201 | 41,567 | -- | -- | 96% | Approved | — |
Source: Jazz Pharmaceuticals plc, Form 8-K, filed with the SEC on July 25, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
559 asset managers disclosed a vote on at least one Jazz Pharmaceuticals plc item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect four nominees for director named below to hold office until the 2028 Annual General Meeting of Shareholders: Jennifer E. Cook
Jazz Pharmaceuticals plc’s own tally for this item (“Elect Director: Jennifer E. Cook”): 49,838,761 for, 1,472,373 against, per its Form 8-K filed July 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 131 asset managers below reported 23,839,863 for, 221,758 against, 11,084 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,954,886 | 0 | 0 | 0 | For |
| BlackRock | 2,882,483 | 0 | 0 | 0 | For |
| Capital Group | 2,000,000 | 0 | 0 | 0 | For |
| Fidelity | 1,715,527 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,504,445 | 0 | 0 | 0 | For |
| JPMorgan | 1,365,084 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 820,993 | 0 | 0 | 0 | For |
| Dimensional | 767,053 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 752,289 | 0 | 0 | 0 | For |
| Charles Schwab | 581,372 | 0 | 0 | 0 | For |
| State Street | 460,040 | 0 | 0 | 0 | For |
| TIAA | 370,800 | 0 | 0 | 0 | For |
| Pear Tree Funds | 310,900 | 0 | 0 | 0 | For |
| Transamerica | 307,999 | 0 | 0 | 0 | For |
| SEI | 249,696 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 243,056 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 237,159 | 0 | 0 | 0 | For |
| John Hancock | 233,511 | 0 | 0 | 0 | For |
| American Century | 212,264 | 0 | 0 | 0 | For |
| First Trust | 210,400 | 0 | 0 | 0 | For |
| AQR | 155,517 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 148,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 140,877 | 0 | 0 | 0 | For |
| ETF Series Solutions | 12,702 | 126,614 | 0 | 0 | Mixed |
| Jackson National | 128,687 | 0 | 0 | 0 | For |
Showing the 25 largest of 131 asset managers. All 131 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: To elect four nominees for director named below to hold office until the 2028 Annual General Meeting of Shareholders: Norbert G. Riedel, Ph.D.
Jazz Pharmaceuticals plc’s own tally for this item (“Elect Director: Norbert G. Riedel, Ph.D.”): 46,521,583 for, 4,787,903 against, per its Form 8-K filed July 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 131 asset managers below reported 22,730,805 for, 1,330,816 against, 11,084 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,954,885 | 1 | 0 | 0 | For |
| BlackRock | 2,882,483 | 0 | 0 | 0 | For |
| Capital Group | 2,000,000 | 0 | 0 | 0 | For |
| Fidelity | 1,715,527 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,504,445 | 0 | 0 | 0 | For |
| JPMorgan | 1,365,084 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 820,993 | 0 | 0 | 0 | For |
| Dimensional | 767,053 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 752,289 | 0 | 0 | 0 | For |
| Charles Schwab | 581,372 | 0 | 0 | 0 | For |
| State Street | 0 | 460,040 | 0 | 0 | Against |
| TIAA | 0 | 370,800 | 0 | 0 | Against |
| Pear Tree Funds | 310,900 | 0 | 0 | 0 | For |
| Transamerica | 307,999 | 0 | 0 | 0 | For |
| SEI | 249,696 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 225,128 | 17,928 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 237,159 | 0 | 0 | 0 | For |
| John Hancock | 233,511 | 0 | 0 | 0 | For |
| American Century | 212,264 | 0 | 0 | 0 | For |
| First Trust | 210,400 | 0 | 0 | 0 | For |
| AQR | 155,517 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 148,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 140,877 | 0 | 0 | 0 | For |
| ETF Series Solutions | 12,702 | 126,614 | 0 | 0 | Mixed |
| Jackson National | 128,687 | 0 | 0 | 0 | For |
Showing the 25 largest of 131 asset managers. All 131 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect four nominees for director named below to hold office until the 2028 Annual General Meeting of Shareholders: Patrick G. Enright
Jazz Pharmaceuticals plc’s own tally for this item (“Elect Director: Patrick G. Enright”): 49,122,808 for, 2,186,963 against, per its Form 8-K filed July 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 131 asset managers below reported 23,821,934 for, 239,687 against, 11,084 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,954,885 | 1 | 0 | 0 | For |
| BlackRock | 2,882,483 | 0 | 0 | 0 | For |
| Capital Group | 2,000,000 | 0 | 0 | 0 | For |
| Fidelity | 1,715,527 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,504,445 | 0 | 0 | 0 | For |
| JPMorgan | 1,365,084 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 820,993 | 0 | 0 | 0 | For |
| Dimensional | 767,053 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 752,289 | 0 | 0 | 0 | For |
| Charles Schwab | 581,372 | 0 | 0 | 0 | For |
| State Street | 460,040 | 0 | 0 | 0 | For |
| TIAA | 370,800 | 0 | 0 | 0 | For |
| Pear Tree Funds | 310,900 | 0 | 0 | 0 | For |
| Transamerica | 307,999 | 0 | 0 | 0 | For |
| SEI | 249,696 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 225,128 | 17,928 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 237,159 | 0 | 0 | 0 | For |
| John Hancock | 233,511 | 0 | 0 | 0 | For |
| American Century | 212,264 | 0 | 0 | 0 | For |
| First Trust | 210,400 | 0 | 0 | 0 | For |
| AQR | 155,517 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 148,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 140,877 | 0 | 0 | 0 | For |
| ETF Series Solutions | 12,702 | 126,614 | 0 | 0 | Mixed |
| Jackson National | 128,687 | 0 | 0 | 0 | For |
Showing the 25 largest of 131 asset managers. All 131 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect four nominees for director named below to hold office until the 2028 Annual General Meeting of Shareholders: Seamus Mulligan
Jazz Pharmaceuticals plc’s own tally for this item (“Elect Director: Seamus Mulligan”): 49,488,355 for, 1,821,942 against, per its Form 8-K filed July 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 131 asset managers below reported 23,948,803 for, 112,818 against, 11,084 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,954,886 | 0 | 0 | 0 | For |
| BlackRock | 2,882,483 | 0 | 0 | 0 | For |
| Capital Group | 2,000,000 | 0 | 0 | 0 | For |
| Fidelity | 1,715,527 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,504,445 | 0 | 0 | 0 | For |
| JPMorgan | 1,365,084 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 820,993 | 0 | 0 | 0 | For |
| Dimensional | 767,053 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 752,289 | 0 | 0 | 0 | For |
| Charles Schwab | 581,372 | 0 | 0 | 0 | For |
| State Street | 460,040 | 0 | 0 | 0 | For |
| TIAA | 370,800 | 0 | 0 | 0 | For |
| Pear Tree Funds | 310,900 | 0 | 0 | 0 | For |
| Transamerica | 307,999 | 0 | 0 | 0 | For |
| SEI | 249,696 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 225,128 | 17,928 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 237,159 | 0 | 0 | 0 | For |
| John Hancock | 233,511 | 0 | 0 | 0 | For |
| American Century | 212,264 | 0 | 0 | 0 | For |
| First Trust | 210,400 | 0 | 0 | 0 | For |
| AQR | 155,517 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 148,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 140,877 | 0 | 0 | 0 | For |
| ETF Series Solutions | 139,316 | 0 | 0 | 0 | For |
| Jackson National | 128,687 | 0 | 0 | 0 | For |
Showing the 25 largest of 131 asset managers. All 131 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders. pursuant to the statutory pre-emption right that would otherwise apply.
Jazz Pharmaceuticals plc’s own tally for this item (“4. To grant our board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right t”): 53,607,244 for, 2,159,201 against — passed, per its Form 8-K filed July 25, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Jazz Pharmaceuticals plc’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Authorize Issue of Equity without Pre-emptive Rights” (4 managers, 1,450,797 for).
The 129 asset managers below reported 22,570,390 for, 81,518 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,954,886 | 0 | 0 | 0 | For |
| BlackRock | 2,882,483 | 0 | 0 | 0 | For |
| Capital Group | 2,000,000 | 0 | 0 | 0 | For |
| Fidelity | 1,715,527 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,504,445 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 820,993 | 0 | 0 | 0 | For |
| Dimensional | 767,053 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 752,289 | 0 | 0 | 0 | For |
| Charles Schwab | 581,372 | 0 | 0 | 0 | For |
| State Street | 460,040 | 0 | 0 | 0 | For |
| TIAA | 370,800 | 0 | 0 | 0 | For |
| Pear Tree Funds | 310,900 | 0 | 0 | 0 | For |
| Transamerica | 307,999 | 0 | 0 | 0 | For |
| SEI | 249,696 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 225,128 | 17,928 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 237,159 | 0 | 0 | 0 | For |
| John Hancock | 233,511 | 0 | 0 | 0 | For |
| American Century | 212,264 | 0 | 0 | 0 | For |
| First Trust | 210,400 | 0 | 0 | 0 | For |
| AQR | 155,517 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 148,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 140,877 | 0 | 0 | 0 | For |
| ETF Series Solutions | 126,614 | 12,702 | 0 | 0 | Mixed |
| Jackson National | 128,687 | 0 | 0 | 0 | For |
| Goldman Sachs | 120,317 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 17 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 91.2% for (July 25, 2024 meeting) ▲ 3.2 pts
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement.
Jazz Pharmaceuticals plc’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement”): 48,261,149 for, 2,887,574 against — passed, per its Form 8-K filed July 25, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved as follows:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,954,885 | 1 | 0 | 0 | For |
| BlackRock | 2,882,483 | 0 | 0 | 0 | For |
| Capital Group | 2,000,000 | 0 | 0 | 0 | For |
| Fidelity | 1,715,527 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,504,445 | 0 | 0 | 0 | For |
| JPMorgan | 1,365,084 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 820,993 | 0 | 0 | 0 | For |
| Dimensional | 767,053 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 752,289 | 0 | 0 | 0 | For |
| Charles Schwab | 581,372 | 0 | 0 | 0 | For |
| State Street | 460,040 | 0 | 0 | 0 | For |
| TIAA | 370,800 | 0 | 0 | 0 | For |
| Pear Tree Funds | 310,900 | 0 | 0 | 0 | For |
| Transamerica | 307,999 | 0 | 0 | 0 | For |
| SEI | 249,696 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 243,056 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 237,159 | 0 | 0 | 0 | For |
| John Hancock | 233,511 | 0 | 0 | 0 | For |
| American Century | 0 | 212,264 | 0 | 0 | Against |
| First Trust | 210,400 | 0 | 0 | 0 | For |
| AQR | 155,517 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 148,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 140,877 | 0 | 0 | 0 | For |
| ETF Series Solutions | 12,702 | 126,614 | 0 | 0 | Mixed |
| Jackson National | 128,687 | 0 | 0 | 0 | For |
Fund voting reports, all 130 managers: 23,709,053 for, 352,713 against, 11,084 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 2,042,492 | 0 | 0 | 0 | For |
| BlackRock | 1,972,599 | 501 | 0 | 0 | For |
| State Street | 1,737,829 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 1,706,469 | 0 | 0 | 0 | For |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,573,540 | 0 | 0 | 0 | For |
| LSV ASSET MANAGEMENT | 1,464,705 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,162,246 | 0 | 0 | 0 | For |
| Swedbank Robur Fonder AB | 0 | 1,074,092 | 0 | 0 | Against |
| GOLDENTREE ASSET MANAGEMENT LP | 782,280 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 717,837 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 712,428 | 0 | 0 | 0 | For |
| GMT CAPITAL CORP | 696,500 | 0 | 0 | 0 | For |
| Fidelity | 687,478 | 0 | 0 | 0 | For |
| Charles Schwab | 587,069 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 623 | 555,704 | 0 | 0 | Against |
| John Hancock | 547,566 | 0 | 0 | 0 | For |
| THOMPSON SIEGEL & WALMSLEY LLC | 536,752 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 517,972 | 0 | 0 | 0 | For |
| Estuary Capital Management LP | 462,328 | 0 | 0 | 0 | For |
| Northern Trust | 445,882 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 440,791 | 0 | 0 | 0 | For |
| Nuveen | 424,967 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 419,003 | 0 | 0 | 0 | For |
| AQR | 378,575 | 0 | 0 | 0 | For |
| SEI | 372,774 | 0 | 0 | 0 | For |
Institutional-manager reports, all 448 managers: 28,710,323 for, 2,182,523 against, 148,326 abstained, 3,743 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 98.0% for (July 25, 2024 meeting) ▲ 0.3 pts
Description as filed by funds: To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2025 and to authorize, in a binding vote, the Board of Directors, acting through the audit committee, to determine KPMG's remuneration.
Jazz Pharmaceuticals plc’s own tally for this item (“2. To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as our independent auditors for the fiscal year ending December 31, 2025 and to authorize, in a binding vote, our board of directors, acting ”): 54,773,976 for, 996,901 against — passed, per its Form 8-K filed July 25, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 133 asset managers below reported 23,980,442 for, 126,868 against, 11,084 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,954,886 | 0 | 0 | 0 | For |
| BlackRock | 2,882,483 | 0 | 0 | 0 | For |
| Capital Group | 2,000,000 | 0 | 0 | 0 | For |
| Fidelity | 1,715,527 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,504,445 | 0 | 0 | 0 | For |
| JPMorgan | 1,365,084 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 820,993 | 0 | 0 | 0 | For |
| Dimensional | 767,053 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 752,289 | 0 | 0 | 0 | For |
| Charles Schwab | 581,372 | 0 | 0 | 0 | For |
| State Street | 460,040 | 0 | 0 | 0 | For |
| TIAA | 370,800 | 0 | 0 | 0 | For |
| Pear Tree Funds | 310,900 | 0 | 0 | 0 | For |
| Transamerica | 307,999 | 0 | 0 | 0 | For |
| SEI | 249,696 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 243,056 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 237,159 | 0 | 0 | 0 | For |
| John Hancock | 233,511 | 0 | 0 | 0 | For |
| American Century | 212,264 | 0 | 0 | 0 | For |
| First Trust | 210,400 | 0 | 0 | 0 | For |
| AQR | 155,517 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 148,583 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 140,877 | 0 | 0 | 0 | For |
| ETF Series Solutions | 12,702 | 126,614 | 0 | 0 | Mixed |
| Jackson National | 128,687 | 0 | 0 | 0 | For |
Showing the 25 largest of 133 asset managers. All 133 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 1 item from the meeting of July 23, 2026, which belongs to the 2026-2027 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,631,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.82% |
| 2 | BlackRock | 4.75% |
| 3 | Capital Group | 3.30% |
| 4 | Fidelity | 2.83% |
| 5 | Capitol Series Trust | 2.48% |
| 6 | JPMorgan | 2.25% |
| 7 | Columbia Threadneedle | 1.35% |
| 8 | Dimensional | 1.27% |
| 9 | Pacer Funds Trust | 1.24% |
| 10 | Charles Schwab | 0.96% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 3.37% |
| 2 | BlackRock | 3.25% |
| 3 | State Street | 2.87% |
| 4 | EcoR1 Capital, LLC | 2.81% |
| 5 | FULLER & THALER ASSET MANAGEMENT, INC. | 2.60% |
| 6 | LSV ASSET MANAGEMENT | 2.42% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.92% |
| 8 | Swedbank Robur Fonder AB | 1.77% |
| 9 | GOLDENTREE ASSET MANAGEMENT LP | 1.29% |
| 10 | Vestal Point Capital, LP | 1.18% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 5,917,142 | 9.76% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 5,591,700 | 9.22% | Form 13F, quarter ended March 31, 2026 |
| FMR (Fidelity) | 2,275,762 | 3.75% | Form 13F, quarter ended March 31, 2026 |
| Franklin Templeton | 1,958,940 | 3.23% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 1,895,215 | 3.13% | Form 13F, quarter ended March 31, 2026 |
| State Street | 1,891,646 | 3.12% | Form 13F, quarter ended March 31, 2026 |
| BNY Mellon | 1,679,371 | 2.77% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 1,343,944 | 2.22% | Form 13F, quarter ended March 31, 2026 |
| Seamus C. Mulligan | 1,303,369 | 2.15% | Proxy statement (DEF 14A), table as of May 25, 2026 |
| Bruce C. Cozadd | 773,799 | 1.28% | Proxy statement (DEF 14A), table as of May 25, 2026 |
Percentages above are of 60,631,000 shares outstanding, as reported by Jazz Pharmaceuticals plc on its Form 10-K dated December 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Jazz Pharmaceuticals plc's shareholder meeting held July 24, 2025, in the 2025-2026 proxy season, 559 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 4,011 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's… — Jazz Pharmaceuticals plc's filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Jazz Pharmaceuticals plc's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on July 25, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Jazz Pharmaceuticals plc’s 10-K dated December 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Jazz Pharmaceuticals plc proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Jazz Pharmaceuticals (JAZZ) 2025 Annual Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/jazz-pharmaceuticals-plc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.